Invivyd (IVVD) Non Operating Income (2021 - 2026)
Invivyd's (IVVD) quarterly Non Operating Income came in at $1.5 million in Q4 2025, up 88.93% YoY from $786000.0 in Q4 2024, and up 168.54% on a QoQ basis from $553000.0 in Q3 2025.
Invivyd (IVVD) Non Operating Income (2021 - 2026) Analysis & Trends
Invivyd (IVVD) has 5 years of Non Operating Income data on file, last reported at $1.5 million in Q4 2025.
- Quarterly Non Operating Income rose 88.93% year-over-year to $1.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.1 million (down 55.82% YoY) and the FY2025 annual result came in at $3.1 million, down 55.82% from the prior year.
- Non Operating Income grew to $1.5 million in Q4 2025, from $553000.0 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $3.8 million in Q1 2023 to a low of $9000.0 in Q1 2021.
- A 5-year average of $1.5 million and a median of $1.1 million in 2024 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2022 — Non Operating Income soared 7479.17% — and 2025, when it slumped 80.0%.
- Tracing IVVD's Non Operating Income over 5 years: stood at $48000.0 in 2021, then soared by 7479.17% to $3.6 million in 2022, then declined by 14.84% to $3.1 million in 2023, then tumbled by 74.63% to $786000.0 in 2024, then surged by 88.93% to $1.5 million in 2025.
- The last three Non Operating Income figures came in at $1.5 million (Q4 2025), $553000.0 (Q3 2025), and $400000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Invivyd | 212.23 Mn | 52.15 Mn | 13.01 Mn | 1.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.43 Mn |
| Dec 31, 2025 | 1.49 Mn |
| Sep 30, 2025 | 553,000.00 |
| Jun 30, 2025 | 400,000.00 |
| Mar 31, 2025 | 633,000.00 |
| Dec 31, 2024 | 786,000.00 |
| Sep 30, 2024 | 1.57 Mn |
| Jun 30, 2024 | 2.00 Mn |
| Mar 31, 2024 | 2.59 Mn |
| Dec 31, 2023 | 3.10 Mn |
| Sep 30, 2023 | 3.62 Mn |
| Jun 30, 2023 | 3.65 Mn |
| Mar 31, 2023 | 3.75 Mn |
| Dec 31, 2022 | 3.64 Mn |
| Sep 30, 2022 | 2.24 Mn |
| Jun 30, 2022 | 759,000.00 |
| Mar 31, 2022 | 73,000.00 |
| Dec 31, 2021 | 48,000.00 |
| Sep 30, 2021 | 43,000.00 |
| Jun 30, 2021 | 18,000.00 |